Shots:

• The P-III Archway study involves assessing the efficacy and safety of Port Delivery System with ranibizumab (PDS)- refilled q6w at fixed intervals vs monthly IVT of ranibizumab (0.5mg) in 418 people with nAMD
• The P-III Archway study resulted in meeting its 1EP i.e. patients achieved visual acuity outcomes equivalent and is well tolerated with a favorable benefit-risk profile. The 1EP is changed in BCVA score @36wks. & @40wks. while 2EPs include safety; overall change in BCVA from baseline; and change from baseline in center point thickness over time
• Additionally- the Portal study is evaluating the long-term safety and tolerability of PDS for nAMD. PDS is a permanent refillable eye implant- designed to continuously release a customized formulation of ranibizumab into the eye over time

Click here ­to­ read full press release/ article 

Ref: Roche | Image: Roche